MESSAGE
| DATE | 2018-02-07 |
| FROM | From: "APhA - American Pharmacists Association"
|
| SUBJECT | Subject: [Hangout - NYLXS] Immunizing Pharmacists News - February 7, 2018
|
From hangout-bounces-at-nylxs.com Mon Feb 12 11:46:42 2018
Return-Path:
X-Original-To: archive-at-mrbrklyn.com
Delivered-To: archive-at-mrbrklyn.com
Received: from www2.mrbrklyn.com (www2.mrbrklyn.com [96.57.23.82])
by mrbrklyn.com (Postfix) with ESMTP id 8499716113A;
Mon, 12 Feb 2018 11:46:41 -0500 (EST)
X-Original-To: hangout-at-www2.mrbrklyn.com
Delivered-To: hangout-at-www2.mrbrklyn.com
Received: by mrbrklyn.com (Postfix, from userid 1000)
id 311C7161134; Mon, 12 Feb 2018 11:46:38 -0500 (EST)
Resent-From: Ruben Safir
Resent-Date: Mon, 12 Feb 2018 11:46:38 -0500
Resent-Message-ID: <20180212164638.GA27088-at-www2.mrbrklyn.com>
Resent-To: hangout-at-mrbrklyn.com
X-Original-To: ruben-at-mrbrklyn.com
Delivered-To: ruben-at-mrbrklyn.com
Received: from mail79-176.us1.msgfocus.com (mail79-176.us1.msgfocus.com
[81.29.79.176]) by mrbrklyn.com (Postfix) with ESMTP id 55434161132
for ; Wed, 7 Feb 2018 18:36:15 -0500 (EST)
DKIM-Signature: v=1; a=rsa-sha1; c=relaxed/relaxed; s=msgf; d=msgfocus.com;
h=Subject:X-Mailer:Message-ID:Reply-To:To:List-Unsubscribe:From:Date:MIME-Version:Content-Type;
bh=A0uP672XFZfZQwsw9LUpbcPcTGI=;
b=tGv2iao15C7JkDIqTnxU6xpkN4dnwMa7GSHLN6Cxa4aii7cL5vbu28lto21oLG2CwBnNDBPWSzyi
J01o/kMI4q7PmzCLwYm4UVcnz7HBpqGtft5ULKFuK2iG/QN9wXhPi7ENU7Eyt43q7x/Gmk3zyr+W
nuo+x7D7ZFsKiUVI5WQ=
DKIM-Signature: v=1; a=rsa-sha256; c=relaxed/relaxed; d=aphanet.org; s=hrs-dkim;
t=1518046573; bh=U4EmN5Ma3q+hO2Ke/+QAbhZA747V/wYPYuw9aDL1F8k=;
h=Subject:X-Mailer:Message-ID:Reply-To:To:List-Unsubscribe:From:
Date:MIME-Version:Content-Type;
b=plsh2wIwuo0IJkHht9DCLh3k0zJ2fdJ6oWxw7LuNvu1dsgr72p1FigpiCONgwPYF6
AMxpNpsBcQDcCt0ounNjtI52PakIzG1aLIroUM6fJDjCyStXTaQ/EdjxtobVFmYoAj
L4LV40FZgdlyjv5FNtgL/6mFNa0qzh9HDf2kxNN8=
X-Mailer: MessageFocus v2 launch
Message-ID:
To: ruben-at-mrbrklyn.com
From: "APhA - American Pharmacists Association"
Date: Wed, 7 Feb 2018 23:36:13 +0000
MIME-Version: 1.0
Subject: [Hangout - NYLXS] Immunizing Pharmacists News - February 7, 2018
X-BeenThere: hangout-at-nylxs.com
X-Mailman-Version: 2.1.17
Precedence: list
Reply-To: APhA - American Pharmacists Association
List-Id: NYLXS Tech Talk and Politics
List-Unsubscribe: ,
List-Post:
List-Help:
List-Subscribe: ,
Content-Type: multipart/mixed; boundary="===============0364574100=="
Errors-To: hangout-bounces-at-nylxs.com
Sender: "Hangout"
--===============0364574100==
Content-Type: multipart/alternative; boundary="--17C5E3F746EDDA92B065881187F6"
----17C5E3F746EDDA92B065881187F6
Content-Type: text/plain; charset="UTF-8"
Content-Transfer-Encoding: quoted-printable
If you are having trouble viewing this email, view it online.
Immunizing Pharmacist
News
Widespread Influenza Has Killed 37 Children; CDC Provides Related Media Adv=
isory
CDC has reported in its Weekly U.S. Influenza Surveillance Report, FluView
http://messaging.aphanet.org/c/11tr4hnm9oI29Mi3BPfjx6IMOrF, that as of the =
week ending January 20, influenza has caused nearly 12,000 hospitalizations=
and 37 pediatric deaths since October 1, 2017. Because it takes time for d=
eaths outside of a hospital to be investigated, the reported number of pedi=
atric deaths is likely to be an underestimate.
The geographic spread of influenza in Puerto Rico and 49 states was reporte=
d as widespread; Guam reported regional activity; the District of Columbia =
and one state reported local activity; and the U.S. Virgin Islands reported=
sporadic activity.
On January 26, CDC held an update for the media titled "CDC Update on Flu A=
ctivity." Part of the introductory statement from Dan Jernigan, MD, MPH, di=
rector, Influenza Division, National Center for Immunization and Respirator=
y Diseases, CDC, is reprinted below.
It has been a tough flu season so far, this year. And while flu activity is=
beginning to go down in parts of the country, it remains high for most the=
U.S., with some areas still rising. Most people with influenza are being i=
nfected with the H3N2 influenza virus. And in seasons where H3N2 is the mai=
n cause of influenza, we see more cases, more visits to the doctor, more ho=
spitalizations, and more deaths, especially among older people. This season=
now looking like the 2014=E2=80=9315 season where H3N2 predominated. ... W=
e=E2=80=99ve experienced two notable characteristics of flu this season: Th=
e first is that flu activity became widespread within almost all states and=
jurisdictions at the same time. The second is that flu activity has now st=
ayed at the same level for 3 weeks in a row, with 49 states reporting wides=
pread activity, each week, for 3 weeks. We often see different parts of the=
country =E2=80=9Clight up=E2=80=9D at different times, but for the past 3 =
weeks, the entire country has been experiencing lots of flu, all at the sam=
e time.
Access the complete transcript or audio recording
http://messaging.aphanet.org/c/11tr4pa4OdSx7dlBKYNo3vv59mS from this media =
advisory.
Influenza vaccination is recommended for everyone six months of age and old=
er. If you don't provide influenza vaccination in your clinic, please recom=
mend vaccination to your patients and refer them to a clinic or pharmacy th=
at provides vaccines or to the HealthMap Vaccine Finder
http://messaging.aphanet.org/c/11tr4wWNt3324Ep9U8lszUhnui5 to locate sites =
near their workplaces or homes that offer influenza vaccination services.
Following is a list of resources related to influenza disease and vaccinati=
on for healthcare professionals and the public:
CDC's Seasonal Flu web section
http://messaging.aphanet.org/c/11tr4MweMHo1ZwwgcrrBCHPYa8v
CDC's FluView web section
http://messaging.aphanet.org/c/11tr4UiXrwywWXzOlAZG96Cgv3I
CDC's Free Resources related to influenza
http://messaging.aphanet.org/c/11tr525G6lJ1UoDmuKxKFvoyPYV
IAC's handouts related to influenza
http://messaging.aphanet.org/c/11tr59SoLaTwRPGUDU5PbUaRaU8
HealthMap Vaccine Finder
http://messaging.aphanet.org/c/11tr5hF7q041PgKsN3DTIiX9vPl
National Adult and Influenza Immunization Summit
http://messaging.aphanet.org/c/11tr5prQ4PewMHO0WdbYeHJrQKy website
The Summit Buzz
http://messaging.aphanet.org/c/11tr5xeyJEp1K8Rz5mK2L6vKbFL Newsletter of th=
e National Adult and Influenza Immunization Summit
Influenza Vaccine Availability Tracking System=E2=80=94IVATS
http://messaging.aphanet.org/c/11tr5F1hotzwHzV7ewi7hvi2wAY a resource for h=
ealthcare settings looking to purchase influenza vaccine
Source: Immunization Action Coalition. IAC Express. Issue No. 1347. January=
31, 2018.
CDC Publishes ACIP Recommendations for Use of Herpes Zoster Vaccines in MMWR
CDC published Recommendations of the Advisory Committee on Immunization Pra=
ctices for Use of Herpes Zoster Vaccines
http://messaging.aphanet.org/c/11tr5MO03iK1F0YFnFQbNU4kRwb in the January 2=
6 issue of MMWR (pages 103=E2=80=938). The "Introduction" and "Clinical Gui=
dance" sections are reprinted below:
Introduction
On October 20, 2017, Zoster Vaccine Recombinant, Adjuvanted (Shingrix, Glax=
oSmithKline), a 2-dose, subunit vaccine containing recombinant glycoprotein=
E in combination with a novel adjuvant (AS01B), was approved by the Food a=
nd Drug Administration for the prevention of herpes zoster in adults aged =
=E2=89=A550 years. The vaccine consists of 2 doses (0.5 mL each), administe=
red intramuscularly, 2=E2=80=936 months apart. On October 25, 2017, the Adv=
isory Committee on Immunization Practices (ACIP) recommended the recombinan=
t zoster vaccine (RZV) for use in immunocompetent adults aged =E2=89=A550 y=
ears.
Herpes zoster is a localized, usually painful, cutaneous eruption resulting=
from reactivation of latent varicella zoster virus (VZV). Herpes zoster is=
common: approximately one million cases occur each year in the United Stat=
es. The incidence increases with age, from five cases per 1,000 population =
in adults aged 50=E2=80=9359 years to 11 cases per 1,000 population in pers=
ons aged =E2=89=A580 years. Postherpetic neuralgia, commonly defined as per=
sistent pain for at least 90 days following the resolution of the herpes zo=
ster rash, is the most common complication and occurs in 10%=E2=80=9313% of=
herpes zoster cases in persons aged >50 years. Among persons with herpes z=
oster, the risk for developing postherpetic neuralgia also increases with a=
ge.
Zoster Vaccine Live (ZVL) (Zostavax, Merck and Co., Inc.), a 1-dose live at=
tenuated strain of VZV, is licensed for the prevention of herpes zoster in =
immunocompetent adults aged =E2=89=A550 years and is recommended by the ACI=
P for use in immunocompetent adults aged =E2=89=A560 years. Since licensure=
, vaccine coverage has increased each year, and by 2016, 33% of adults aged=
=E2=89=A560 years reported receipt of the vaccine (CDC, provisional unpubl=
ished data). ACIP considered use of RZV, as well as existing recommendation=
s, to develop vaccination policy which would be safe and reduce disease bur=
den. This report serves as a supplement to the 2008 Prevention of Herpes Zo=
ster Recommendations of ACIP for the use of ZVL in adults aged =E2=89=A560 =
years and subsequent updates; it outlines recent ACIP recommendations as we=
ll as guidance for use of RZV and ZVL in adults.
Clinical Guidance
General use. RZV may be used in adults aged =E2=89=A550 years, irrespective=
of prior receipt of varicella vaccine or ZVL, and does not require screeni=
ng for a history of chickenpox (varicella). ZVL remains a recommended vacci=
ne for prevention of herpes zoster in immunocompetent adults aged =E2=89=A5=
60 years. Care should be taken not to confuse ZVL, which is stored in the f=
reezer and administered subcutaneously, with RZV, which is stored in the re=
frigerator and administered intramuscularly.
Dosing schedule. Following the first dose of RZV, the second dose should be=
given 2=E2=80=936 months later. The vaccine series need not be restarted i=
f more than 6 months have elapsed since the first dose; however, the effica=
cy of alternative dosing regimens has not been evaluated, data regarding th=
e safety of alternative regimens are limited, and individuals might remain =
at risk for herpes zoster during a longer than recommended interval between=
doses 1 and 2. If the second dose of RZV is given less than 4 weeks after =
the first, the second dose should be repeated. Two doses of the vaccine are=
necessary regardless of prior history of herpes zoster or prior receipt of=
ZVL.
Timing of RZV for persons previously vaccinated with ZVL. Age and time sinc=
e receipt of ZVL may be considered to determine when to vaccinate with RZV.=
Studies examined the safety and immunogenicity of RZV vaccination administ=
ered =E2=89=A55 years after ZVL; shorter intervals have not been studied. H=
owever, there are no data or theoretical concerns to indicate that RZV woul=
d be less safe or less effective when administered at an interval of <5 yea=
rs. Clinical trials indicated lower efficacy of ZVL in adults aged =E2=89=
=A570 years; therefore, a shorter interval may be considered based on the r=
ecipient=E2=80=99s age when ZVL was administered. Based on expert opinion, =
RZV should not be given <2 months after receipt of ZVL.
Coadministration with other vaccines. CDC=E2=80=99s general best practice g=
uidelines for immunization advise that recombinant and adjuvanted vaccines,=
such as RZV, can be administered concomitantly, at different anatomic site=
s, with other adult vaccines. Concomitant administration of RZV with Fluari=
x Quadrivalent (influenza vaccine) (QIV) has been studied, and there was no=
evidence for interference in the immune response to either vaccine or safe=
ty concerns. Evaluation of coadministration of RZV with 23-valent pneumococ=
cal polysaccharide vaccine (PPSV23, Pneumovax23) and tetanus toxoid, reduce=
d diphtheria toxoid, and acellular pertussis vaccine, adsorbed (Tdap, Boost=
rix) is ongoing. The safety and efficacy of administration of two adjuvante=
d vaccines (e.g., RZV and adjuvanted influenza vaccine [Fluad]), either con=
comitantly or at other intervals, have not been evaluated.
Counseling for reactogenicity. Before vaccination, providers should counsel=
RZV recipients about expected systemic and local reactogenicity. Reactions=
to the first dose did not strongly predict reactions to the second dose; v=
accine recipients should be encouraged to complete the series even if they =
experienced a grade 1=E2=80=933 reaction to the first dose of RZV. The impa=
ct of prophylactic analgesics in conjunction with RZV has not been studied.
Access the complete recommendation: Recommendations of the Advisory Committ=
ee on Immunization Practices for Use of Herpes Zoster Vaccines
http://messaging.aphanet.org/c/11tr5UAII7UwCs2dwPogkiQDcro.
Source: Immunization Action Coalition. IAC Express. Issue No. 1347. January=
31, 2018.
Draft Agenda for February ACIP Meeting Available
http://messaging.aphanet.org/c/11tr6aaa1Mfwxk9jP8upn6pdShO
ACIP will hold its next meeting on February 21=E2=80=9322 in Atlanta. The d=
raft agenda is now available online. To attend the meeting, ACIP attendees =
(participants and visitors) must register online. The registration deadline=
for non-U.S. citizens is January 24; for U.S. citizens, it's February 5. R=
egistration is not required to watch the meeting via webcast or listen to t=
he proceedings via phone. See the first link below for the toll-free phone =
number and passcode.
Related Links
ACIP Meeting Information
http://messaging.aphanet.org/c/11tr6hWSGBq1uLcRYi2tTvbwdd1 web page
February meeting registration information
http://messaging.aphanet.org/c/11tr6pJBlqAwscgq7rAypTXOy8e
Source: Immunization Action Coalition. IAC Express. Issue No. 1346. January=
24, 2018.
Large Review Study Investigates the Effectiveness of Patient Reminders Rega=
rding Vaccination
On January 18, the Cochrane Database of Systemic Reviews published a large =
review and meta-analysis by Vann Jacobson et al. titled Patient reminder an=
d recall interventions to improve immunization rates.
http://messaging.aphanet.org/c/11tr6xwk0fL1pDjYgB8CWiK6T3r "Background" and=
"Conclusions" sections of the abstract are reprinted below:
Background
Immunization rates for children and adults are rising, but coverage levels =
have not reached optimal goals. As a result, vaccine-preventable diseases s=
till occur. In an era of increasing complexity of immunization schedules, r=
ising expectations about the performance of primary care, and large demands=
on primary care providers, it is important to understand and promote inter=
ventions that work in primary care settings to increase immunization covera=
ge. One common theme across immunization programs in many nations involves =
the challenge of implementing a population-based approach and identifying a=
ll eligible recipients, for example the children who should receive the mea=
sles vaccine. However, this issue is gradually being addressed through the =
availability of immunization registries and electronic health records. A se=
cond common theme is identifying the best strategies to promote high vaccin=
ation rates. Three types of strategies have been studied: (1) patient-orien=
ted interventions, such as patient reminder or recall, (2) provider interve=
ntions, and (3) system interventions, such as school laws. One of the most =
prominent intervention strategies, and perhaps best studied, involves patie=
nt reminder or recall systems. This is an update of a previously published =
review.
Authors' Conclusions
Patient reminder and recall systems, in primary care settings, are likely t=
o be effective at improving the proportion of the target population who rec=
eive immunizations.
Access Patient reminder and recall interventions to improve immunization ra=
tes
http://messaging.aphanet.org/c/11tr6Fj2F4Vwn4nwpKGHsHwpdYE.
Related Link
MedPage Today: Patient Reminders Effective at Improving Receipt of Vaccines=
=E2=80=94Text messages, postcards, and autodialer calls worked best
http://messaging.aphanet.org/c/11tr6N5LjU61kvr4yUeLZ6iHyTR
Source: Immunization Action Coalition. IAC Express. Issue No. 1347. January=
31, 2018.
Southeast Michigan Hepatitis A Outbreak Continues to Rise; Now With 677 Cas=
es and 22 Deaths
Southeast Michigan=E2=80=99s hepatitis A outbreak, which has continued to r=
ise, now has 677 cases and 22 deaths across 15 counties, according to the M=
ichigan Department of Health and Human Services. The outbreak, which began =
in August 2016, has appeared to spread through person-to-person contact and=
drug use. The national shortage of the hepatitis A vaccine has led to prio=
ritizing vaccination efforts to reach the people who are the most at risk a=
nd the areas with the most cases. Outside of Michigan, San Diego has been t=
he hardest hit by a hepatitis A outbreak, with almost 600 cases and 20 deat=
hs since August 2016.
Related Links
Michigan Department of Health and Human Services: Hepatitis A Southeast Mic=
higan Outbreak
http://messaging.aphanet.org/c/11tr6UStYJgwhWuCI3MQvv4ZTP4 (1/17)
CNN: Michigan hit hard by deadly hepatitis A outbreak
http://messaging.aphanet.org/c/11tr72FcDyr1fnyaRdkV1TRieKh (1/16)
San Diego County Health and Human Services Agency: San Diego Hepatitis A Ou=
tbreak
http://messaging.aphanet.org/c/11tr7arVinBwcOBJ0mSZyiDAzFu (1/16)
Source: Immunization Action Coalition. IAC Express. Issue No. 1346. January=
24, 2018.
Study Found More Than One Third of People Infected With HIV in U.S. Had Mis=
sed Opportunities to Initiate Hepatitis B Vaccination
On December 26, the Annals of Internal Medicine published an article online=
by John Weiser et al. titled Low Prevalence of Hepatitis B Vaccination Amo=
ng Patients Receiving Medical Care for HIV Infection in the United States, =
2009 to 2012
http://messaging.aphanet.org/c/11tr7ieDXcM1afFh9wr44HpSUAH. Three sections =
of the abstract are reprinted below:
Background
Persons with HIV infection are at increased risk for hepatitis B virus infe=
ction. In 2016, the World Health Organization resolved to eliminate hepatit=
is B as a public health threat by 2030.
Objective
To estimate the prevalence of hepatitis B vaccination among U.S. patients r=
eceiving medical care for HIV infection (=E2=80=9CHIV patients=E2=80=9D).
Conclusion
More than one third of U.S. HIV patients had missed opportunities to initia=
te hepatitis B vaccination. Meeting goals for hepatitis B elimination will =
require increased vaccination of HIV patients in all practice settings, par=
ticularly at facilities not funded by RWHAP.
Access the abstract: Low Prevalence of Hepatitis B Vaccination Among Patien=
ts Receiving Medical Care for HIV Infection in the United States, 2009 to 2=
012
http://messaging.aphanet.org/c/11tr7xO5gR7157MnrPxd7uYtAr7.
Source: Immunization Action Coalition. IAC Express. Issue No. 1347. January=
31, 2018.
Canadian Study Finds Significant Association Between Influenza and Acute My=
ocardial Infarction
On January 25, the New England Journal of Medicine published an article onl=
ine by Jeffrey Kwong et al. titled Acute Myocardial Infarction after Labora=
tory-Confirmed Influenza Infection
http://messaging.aphanet.org/c/11tr7FANVGhw2yPVAZ5hDTKLVmk. The "Background=
" and "Conclusions" sections of the abstract are reprinted below:
Background
Acute myocardial infarction can be triggered by acute respiratory infection=
s. Previous studies have suggested an association between influenza and acu=
te myocardial infarction, but those studies used nonspecific measures of in=
fluenza infection or study designs that were susceptible to bias. We evalua=
ted the association between laboratory-confirmed influenza infection and ac=
ute myocardial infarction.
Conclusions
We found a significant association between respiratory infections, especial=
ly influenza, and acute myocardial infarction. (Funded by the Canadian Inst=
itutes of Health Research and others.)
Access the abstract: Acute Myocardial Infarction after Laboratory-Confirmed=
Influenza Infection
http://messaging.aphanet.org/c/11tr7NnwAvs0ZZTtK8Dmaix4ghx.
Source: Immunization Action Coalition. IAC Express. Issue No. 1347. January=
31, 2018.
Deadline Extended to February 8=E2=80=A6Nominations Open for the National A=
dult and Influenza Immunization Summit Excellence Awards
The National Adult and Influenza Immunization Summit (NAIIS) is soliciting =
candidates for the 2018 NAIIS Immunization Excellence Awards. The 2018 awar=
ds recognize individuals and organizations that have made extraordinary con=
tributions towards improving vaccination rates within their communities dur=
ing 2017. The awards focus on individuals and organizations that exemplify =
the meaning of the "immunization neighborhood" (collaboration, coordination=
, and communication among immunization stakeholders dedicated to meeting th=
e immunization needs of the patient and protecting the community from vacci=
ne-preventable diseases). Unless an award criteria is specifically focused =
on influenza, it is the intent of the Summit to recognize broader adult imm=
unization activities.
A national winner will be selected for each award category, and, where appr=
opriate, an honorable mention recipient. The winners will be presented with=
their awards at the National Adult and Influenza Immunization Summit meeti=
ng to be held in May 17=E2=80=9318 in Atlanta. The national winner in each =
category will be invited to present their programs at the National Adult an=
d Influenza Immunization Summit meeting.
Access information on the award categories and the nomination form
http://messaging.aphanet.org/c/11tr7VaffkCvXqX1TibqGHjmBcK.
Related Links
NAIIS website
http://messaging.aphanet.org/c/11tr82WXU9N0US0A2rJvd65EW7X
NAIIS newsletter: The Summit Buzz
http://messaging.aphanet.org/c/11tr8aJGyYXvSj48bBhzJuRXh3a
Source: Immunization Action Coalition. IAC Express. Issue No. 1347. January=
31, 2018.
WHO Report on Immunization in Older Adults Worldwide Published in Vaccine
On January 12, Report on WHO meeting on immunization in older adults: Genev=
a, Switzerland, 22=E2=80=9323 March 2017
http://messaging.aphanet.org/c/11tr8iwpdO80PK7GkKPEfTEfBYn, was published o=
nline in Vaccine.
Source: Immunization Action Coalition. IAC Express. Issue No. 1347. January=
31, 2018.
CDC Publishes Report About People Who Erroneously Received an Excess Dosage=
of Yellow Fever Vaccine
CDC published Notes from the Field : Errors in Administration of an Excess =
Dosage of Yellow Fever Vaccine=E2=80=94United States, 2017
http://messaging.aphanet.org/c/11tr8qj7SDivNbbetUnIMiqxWTA in the January 2=
6 issue of MMWR (pages 109=E2=80=9310).
Source: Immunization Action Coalition. IAC Express. Issue No. 1347. January=
31, 2018.
WHO Publishes Report from the December Meeting of the Global Advisory Commi=
ttee on Vaccine Safety in Weekly Epidemiological Record
WHO published a report from the meeting of the Global Advisory Committee on=
Vaccine Safety, held on December 6=E2=80=937, 2017, in the January 19 issu=
e of its Weekly Epidemiological Record. The report is titled Global Advisor=
y Committee on Vaccine Safety, 6=E2=80=937 December 2017.
http://messaging.aphanet.org/c/11tr8y5Qxst0KCeMD3VNiHcQhON
Source: Immunization Action Coalition. IAC Express. Issue No. 1346. January=
24, 2018.
Back to top
Resources
IAC's Recently Updated Clinic Tools: Screening for Vaccine Contraindication=
s and Precautions Web Page Provides Resources From IAC and CDC to Help You =
Assess Whether Your Patients Can Be Vaccinated
Recently updated, IAC's Clinic Tools: Screening for Vaccine Contraindicatio=
ns and Precautions
http://messaging.aphanet.org/c/11tr8FSzchDvI3ikMdtRP5Z8CK0 web page on immu=
nize.org is a collection of resources from IAC and CDC related to vaccine c=
ontraindications and precautions. This web page can be found by selecting t=
he "Clinic Tools" tab (third from the left) in the light gray banner across=
the top of every immunize.org web page and then selecting "Screening for C=
ontraindications" in the drop-down menu.
In the left-hand column of the page you will find IAC's educational materia=
ls related to vaccine administration. From here, you can access IAC's scree=
ning checklists for vaccination as well as links to other related resources=
available on immunize.org. The right-hand column of the page includes reso=
urces from CDC.
Visit the Clinic Tools: Screening for Vaccine Contraindications and Precaut=
ions
http://messaging.aphanet.org/c/11trpvb5qSkqawY8yR7DQEmLQo6 on immunize.org.
Related Links
Clinic Tools
http://messaging.aphanet.org/c/11trpCXO5HuV7Y1GI0FIn394bjj web section on i=
mmunize.org
http://messaging.aphanet.org/c/11trpKKwKwFq5p5eRadMTrVmwew
Clinic Tools: Administering Vaccines
http://messaging.aphanet.org/c/11trpSxfplPV2Q8N0jLRpQHER9J web page
Clinic Tools: Vaccine Storage and Handling
http://messaging.aphanet.org/c/11trq0jY4b0q0hcl9tjVWftXc4W web page
Source: Immunization Action Coalition. IAC Express. Issue No. 1347. January=
31, 2018.
IAC Updates "Administering Vaccines: Dose, Route, Site, and Needle Size=E2=
=80=9D
IAC recently revised Administering Vaccines: Dose, Route, Site, and Needle =
Size
http://messaging.aphanet.org/c/11trq86GJ0aUXIfTiCS0sEgfx09 to incorporate t=
he recently licensed recombinant zoster vaccine (RZV), Shingrix, that is ad=
ministered intramuscularly, as well as the recently licensed hepatitis B va=
ccine (Heplisav-B) that is licensed for use in adults.
Related Links
IAC's educational materials on vaccine administration
http://messaging.aphanet.org/c/11trqfTpnPlpV9jrrMq4Z32xRVm
IAC's Clinic Tools: Administering Vaccines
http://messaging.aphanet.org/c/11trqnG82EvUSAmZAVY9vrOQcQz page
CDC's Vaccine Administration
http://messaging.aphanet.org/c/11trqvsQHtGpQ1qxK5we1QB8xLM web section
CDC's Vaccine Administration e-Learn
http://messaging.aphanet.org/c/11trqDfzmiQUNsu5Tf4iyfnqSGZ
CDC's Resource Library
http://messaging.aphanet.org/c/11trqSP0FXbUIkBcbyarB2W1yxp with 18 brief st=
and-alone videos on vaccine administration
Source: Immunization Action Coalition. IAC Express. Issue No. 1347. January=
31, 2018.
IAC Updates "How to Administer Intramuscular and Subcutaneous Vaccine Injec=
tions" and "How to Administer Intramuscular and Subcutaneous Vaccine Inject=
ions to Adults"
IAC recently updated How to Administer Intramuscular and Subcutaneous Vacci=
ne Injections
http://messaging.aphanet.org/c/11trr0BJkMmpFLEKkHIw7rIjTsC and How to Admin=
ister Intramuscular and Subcutaneous Vaccine Injections to Adults
http://messaging.aphanet.org/c/11trr8orZBwUDcIitRgADQuCenP. Changes were ma=
de to incorporate the recently licensed recombinant zoster vaccine (RZV), S=
hingrix, that is administered intramuscularly, in contrast to the live zost=
er vaccine (LZV), Zostavax, which is administered subcutaneously.
Related Links
IAC's educational materials on vaccine administration
http://messaging.aphanet.org/c/11trrgbaEqHpADLQD0OFafgUzj2
IAC's Clinic Tools: Administering Vaccines
http://messaging.aphanet.org/c/11trrnXTjfRUy4PoMamJGE3cUef page
CDC's Vaccine Administration
http://messaging.aphanet.org/c/11trrvKBY52pvvSWVjUOd2Pvf9s web section
CDC's Vaccine Administration e-Learn
http://messaging.aphanet.org/c/11trrDxkCUcUsWWv4tsSJrBNA4F
CDC's Resource Library
http://messaging.aphanet.org/c/11trrLk3hJnpqo03dD0XfQo5UZS with 18 brief st=
and-alone videos on vaccine administration
Source: Immunization Action Coalition. IAC Express. Issue No. 1347. January=
31, 2018.
Vaccine Education Center Updates Multiple Resources, Including Its Mumps Q&=
A Sheet and Adult Vaccination Booklet
The Vaccine Education Center
http://messaging.aphanet.org/c/11trrT6LWyxUnP3BmMz1MfaofV5 at Children's Ho=
spital of Philadelphia has updated the following three print resources:
"Mumps: What you need to know" addresses mumps disease and vaccination. Thi=
s Q&A sheet now also covers recent college outbreaks and the new ACIP third=
dose recommendation. This piece is part of VEC's Vaccine- and Vaccine Safe=
ty-Related Q&A Sheets series
http://messaging.aphanet.org/c/11trs0TuBnIplg79vW76iDWGAQi, and is availabl=
e in English
http://messaging.aphanet.org/c/11trsgsVV23pg8efOfdflrvhgGI and Spanish
http://messaging.aphanet.org/c/11trsofEzRdUdzhNXoLjRQhzBBV.
=E2=80=9CPrescription for Information=E2=80=9D pads (in English
http://messaging.aphanet.org/c/11trsw2neGopb0lm6yjoof3RWx8 and Spanish
http://messaging.aphanet.org/c/11trsDP5TvyU8roUfHRsUDQahsl) have been updat=
ed to include all recently revised Q&A sheets. Individual sheets can be sen=
t home with patients/parents so they can view the materials online at their=
convenience.
The "Adults and Vaccines: A Lifetime of Health" booklet was updated to incl=
ude information about the new shingles vaccine. Other minor changes were al=
so made, including updated statistics, information about egg allergies, and=
mentions of recent measles and mumps outbreaks. This booklet is also avail=
able in English
http://messaging.aphanet.org/c/11trsLBOykJp5SssoRpxr2CsCny and Spanish
http://messaging.aphanet.org/c/11trsToxd9TU3jw0y0XBXroKXiL.
You can download all VEC resources for free or order print copies from VEC
http://messaging.aphanet.org/c/11trt1bfRZ4p0KzyHavGtQb3idY (some free; most=
for a nominal charge).
In addition, Do I Need to Avoid Being Around Infants After a Shingles Vacci=
ne?
http://messaging.aphanet.org/c/11trt8XYwOeTYbD6Qk3L0eXlD9b from the video s=
eries Talking about Vaccines with Dr. Paul Offit
http://messaging.aphanet.org/c/11trtgKHbDpoVCGEZtBPwDJDY4o has been updated=
to address the new shingles vaccine, Shingrix.
Related Link
Vaccine Education Center at Children's Hospital of Philadelphia
http://messaging.aphanet.org/c/11trtoxpQszTT3Kd8D9U32vWiZB website
Source: Immunization Action Coalition. IAC Express. Issue No. 1347. January=
31, 2018.
Vaccine Education Center Publishes January Issue of Its Newsletter for Heal=
th Care Professionals
The Vaccine Education Center (VEC)
http://messaging.aphanet.org/c/11trtE6Ra6UTNVRjqWg35Q4wYQ1 at Children's Ho=
spital of Philadelphia publishes a monthly immunization-focused newsletter =
titled Vaccine Update for Healthcare Professionals
http://messaging.aphanet.org/c/11trtLTzOW5oLmURA5O7CeQPjLe. The January iss=
ue includes the following articles:
Chasing Seasonal Influenza=E2=80=94The Need for a Universal Influenza Vacci=
ne
http://messaging.aphanet.org/c/11trtTGitLfTINYpJfmc8DD7EGr by Paul A. Offit=
, MD
CDC Issues New Requirements for VFC Vaccine Storage
http://messaging.aphanet.org/c/11tru1t18AqoGf1XSoUgF2ppZBE by IAC executive=
director Deborah L. Wexler, MD
Updated ACIP Recommendations Related to Mumps and Hepatitis B
http://messaging.aphanet.org/c/11tru9fJNpATDG5w1yslbrbIkwR by Charlotte A. =
Moser and Paul A. Offit, MD
Additional articles and resources, including handouts for patients, are ava=
ilable in the full newsletter
http://messaging.aphanet.org/c/11truh2sseLoB794aI0pHPY0Fs4.
Access the sign-up form
http://messaging.aphanet.org/c/11truoPb73VTyycCjRyueeKj0nh to subscribe to =
Vaccine Update for Healthcare Professionals.
Source: Immunization Action Coalition. IAC Express. Issue No. 1347. January=
31, 2018.
CDC, AAP, and AAFP Update and Post Their 14 Childhood-immunization "Basic" =
Disease Fact Sheets in English and Spanish
CDC, the American Academy of Pediatrics, and the American Academy of Family=
Physicians have updated their childhood-immunization =E2=80=9Cbasic=E2=80=
=9D disease fact sheets
http://messaging.aphanet.org/c/11truwBTLT6ovZgat16yKDwBliu in English and S=
panish, and they are now available on CDC=E2=80=99s website.
Each of the 14 fact sheets provides an overview of a vaccine-preventable di=
sease and related vaccine information. These fact sheets were co-developed =
by CDC, AAP and AAFP for use with parents of children 0=E2=80=932 years old=
. They are part of the Provider Resources for Vaccine Conversations with Pa=
rents
http://messaging.aphanet.org/c/11truEoCqIgTtqjICaEDh2iTGdH web section, whi=
ch also includes communication guidance and vaccine safety resources. The f=
act sheets can be viewed online as HTML pages or printed for distribution i=
n clinicians' offices and at community health events.
There are updated fact sheets on the following diseases:
Chickenpox
http://messaging.aphanet.org/c/11truMbl5xroqRngLkcHNr5c18U
Diphtheria
http://messaging.aphanet.org/c/11trv1KMpbMolJun3DiQQeDMGZk
Hepatitis A
http://messaging.aphanet.org/c/11trv9xv40WTjaxVcMQVmDq51Ux
Hepatitis B
http://messaging.aphanet.org/c/11trvhkdIQ7ogBBtlWoZT2cnmPK
Hib
http://messaging.aphanet.org/c/11trvp6WnFhTe2F1v5X4pqYFHKX
Influenza (flu)
http://messaging.aphanet.org/c/11trvwTF2usobtIzEfv8VPKY2Ga
Measles
http://messaging.aphanet.org/c/11trvEGnHjCT8UM7Np3dsexgnBn
Mumps
http://messaging.aphanet.org/c/11trvMt6m8No6lPFWyBhYDjyIwA
Pneumococcal disease
http://messaging.aphanet.org/c/11trvUfP0XXT3MTe5I9mv25R3rN
Polio
http://messaging.aphanet.org/c/11trw22xFN8o1dWMeRHr1qS9on0
Rotavirus
http://messaging.aphanet.org/c/11trw9PgkCiSYF0ko1fvxPErJid
Rubella
http://messaging.aphanet.org/c/11trwpoHEgDSTx7qGklEADd2p8D
Tetanus
http://messaging.aphanet.org/c/11trwxbqj5OnQYaYPtTJ71ZkK3Q
Whooping Cough (pertussis)
http://messaging.aphanet.org/c/11trwEY8XUYSOpewYDrNDqLD4Z3
CDC will be retiring their in-depth disease fact sheets this spring.
Any questions can be sent to CDC by emailing childhoodvaccines-at-cdc.gov
http://messaging.aphanet.org/c/11trwMKRCK9nLQi57MZS9PxVpUg.
Related Link
CDC's Provider Resources for Vaccine Conversations with Parents
http://messaging.aphanet.org/c/11trwUxAhzjSJhlDgWxWGekdKPt web section
Source: Immunization Action Coalition. IAC Express. Issue No. 1346. January=
24, 2018.
IAC's Recently Updated Its Clinic Tools: Administering Vaccines Web Page, t=
he "Go-to" Place for Accessing a Wide Variety of Valuable Resources
IAC's Clinic Tools: Administering Vaccines
http://messaging.aphanet.org/c/11trx2kiWounGIpbq661cD6w5KG web page on immu=
nize.org is the "go-to" place for resources on vaccine administration. Upda=
ted this month, this web page makes it easy to find a wide variety of educa=
tional materials, resources, and tools related to vaccine administration fr=
om IAC and from IAC partner organizations. This web page can be found by se=
lecting the "Clinic Tools" tab (third from the left) in the light gray bann=
er across the top of every immunize.org web page and then selecting "Admini=
stering Vaccines" in the drop-down menu.
In the left-hand column of the page you will find IAC's educational materia=
ls related to vaccine administration. From here, you can access handouts an=
d standing orders as well as links to other related resources available on =
immunize.org.
The right-hand column of the page includes resources from CDC and other par=
tner organizations. For example, the second resource listed under CDC, the =
Vaccination Administration Resource Library,
http://messaging.aphanet.org/c/11trxa71BdESE9sJzfE5J1SOqFT brings readers d=
irectly to the web page with CDC's e-Learn 18 vaccine administration video =
clips. These video clips, ranging from around three to nine minutes in leng=
th, have been excerpted for quick access from the e-Learn course. In this c=
olumn, additional vaccine administration educational resources can be acces=
sed from other IAC partners as well, including the Alliance for Immunizatio=
n in Michigan, California Department of Public Health's EZ-IZ website, and =
the American Academy of Pediatrics.
Visit the Clinic Tools: Administering Vaccines
http://messaging.aphanet.org/c/11trxhTKg2PnBAwhIpcafqF6LB6 web page on immu=
nize.org.
Related Link
View all IAC vaccine administration educational materials.
http://messaging.aphanet.org/c/11trxpGsURZSz1zPRyKeLPrp6wj
Source: Immunization Action Coalition. IAC Express. Issue No. 1346. January=
24, 2018.
Influenza is Spreading and Serious; Please Keep Vaccinating Your Patients
According to CDC, during the week of January 7=E2=80=9313, 2018, influenza =
activity increased in the United States. The geographic spread of influenza=
in Puerto Rico and 49 states was reported as widespread; Guam reported reg=
ional activity; the District of Columbia and one state reported local activ=
ity; and the U.S. Virgin Islands reported sporadic activity. Ten influenza-=
associated pediatric deaths were reported.
Influenza vaccination is recommended for everyone six months of age and old=
er. If you don't provide influenza vaccination in your clinic, please recom=
mend vaccination to your patients and refer them to a clinic or pharmacy th=
at provides vaccines or to the HealthMap Vaccine Finder
http://messaging.aphanet.org/c/11trxxtbzHanwsDo0IijiedHrrw to locate sites =
near their workplaces or homes that offer influenza vaccination services.
Following is a list of resources related to influenza disease and vaccinati=
on for healthcare professionals and the public:
CDC's Seasonal Flu web section
http://messaging.aphanet.org/c/11trxN2CTlvnrkKuj1osl1Mi7hW
CDC's FluView web section
http://messaging.aphanet.org/c/11trxUPlyaFSoLO2saWwRqyAsd9
CDC's Free Resources related to influenza
http://messaging.aphanet.org/c/11try2C4cZQnmcRABkuBnPkSN8m
IAC's handouts related to influenza
http://messaging.aphanet.org/c/11tryaoMRP0SjDV8Ku2FUe7b83z
HealthMap Vaccine Finder
http://messaging.aphanet.org/c/11tryibvwEbnh4YGTDAKqCTtsYM
National Adult and Influenza Immunization Summit
http://messaging.aphanet.org/c/11trypYebtlSew2f2N8OX1FLNTZ website
The Summit Buzz
http://messaging.aphanet.org/c/11tryxKWQiwnbX5NbWGTtqs48Pc Newsletter of th=
e National Adult and Influenza Immunization Summit
Influenza Vaccine Availability Tracking System=E2=80=94IVATS
http://messaging.aphanet.org/c/11tryFxFv7GS9o9ll6eXZPemtKp a resource for h=
ealthcare settings looking to purchase influenza vaccine
Source: Immunization Action Coalition. IAC Express. Issue No. 1346. January=
24, 2018.
Healthcare Ready Releases issue brief entitled Pharmacy and Emergency Prepa=
redness
Healthcare Ready has released an issue brief entitled Pharmacy and Emergenc=
y Preparedness
http://messaging.aphanet.org/c/11tryNko9WRn6PcTufN2we0EOFC. The issue brief=
and a shorter snapshot are attached here. As a component of Resilient and =
Ready: Healthcare=E2=80=99s Impact in Emergency Preparedness
http://messaging.aphanet.org/c/11tryV76OM1S4ggrDpl72CMX9AP, Healthcare Read=
y=E2=80=99s report examining trends in healthcare that are enhancing the pr=
eparedness posture of the healthcare sector, this brief highlights advancem=
ents in the field and novel resources available to pharmacy stakeholders wh=
ile also summarizing emerging challenges.
As last year=E2=80=99s hurricane season and this year=E2=80=99s flu season =
continue to underscore, pharmacies and pharmacists are absolutely indispens=
able components of the healthcare system. This report showcases their effor=
ts and capabilities through this effort.
Be FLUent =E2=80=93 Talk to Your 65+ Patients About Flu Prevention
http://messaging.aphanet.org/c/11trzaGy8qmRZ8nxVIrg5qlxPrf a pharmacist you=
are on the front lines of patient care, and you can play a key role in eng=
aging and informing your older patients about the dangers of flu, as well a=
s the latest strategies for prevention. Be FLUent
http://messaging.aphanet.org/c/11trzitgNfxmWzr64RZkBP7Qams offers a series =
of tools and resources to help you lead the way in protecting adults age 65=
years and older from flu.
Back to top
Education
National AHEC Organization to Sponsor February 15 Webinar Titled "How HPV C=
auses Cancer and Why it Still Matters"
The National AHEC Organization is sponsoring a webinar titled "How HPV Caus=
es Cancer and Why it Still Matters" on February 15 at 3:00 p.m. (ET). Peter=
C. Angeletti, associate professor, University of Nebraska=E2=80=93Lincoln,=
Nebraska Center for Virology, School of Biological Sciences, will explain =
the biology of HPV infection and the mechanism by which HPV causes cancer, =
and then show evidence of different manifestations of HPV-related dysplasia=
. He will also discuss the rationale for adopting an effective public HPV v=
accination strategy and provide evidence for efficacy of the current vaccin=
e.
Registration information
http://messaging.aphanet.org/c/11trzqfZs4HRU0uEe1xp8dU8vhF
Source: Immunization Action Coalition. IAC Express. Issue No. 1347. January=
31, 2018.
Immunize Nevada Sponsors All-day Adult Immunization Summit Webinar on Febru=
ary 16
Immunize Nevada is sponsoring an all-day Adult Immunization Summit webinar
http://messaging.aphanet.org/c/11trzy2I6TSmRrycnb5tECGqQcS on February 16 f=
rom 9:00=E2=80=932:30 p.m. Pacific Time (12:00=E2=80=935:30 p.m. ET). This =
webinar is part of their NILE (Nevada Immunization Learning Exchange) webin=
ar series. The day-long webinar will include four consecutive sessions; reg=
ister individually for each one.
The titles of the four sessions are:
Pharmacists' Role within the Immunization Neighborhood
Adult Immunizations
Pneumococcal Vaccines for Adults
Nevada Web IZ: Adult Immunization Improvement Project
Register on the Immunize Nevada
http://messaging.aphanet.org/c/11trzFPqLJ2ROSBKwkDyb1sJb85
http://messaging.aphanet.org/c/11trzNC9qydmMjFiFubCHqf1w3i Webinars
http://messaging.aphanet.org/c/11trzVoS5nnRJKIQODJHdP1jQYv web page.
Related Link
Immunize Nevada
http://messaging.aphanet.org/c/11trA3bAKcymHbMoXNhLKdNCbTI
Source: Immunization Action Coalition. IAC Express. Issue No. 1346. January=
24, 2018.
NFID and mdBriefCase Group Inc. Offering On-demand CME Activity: "Seasonal =
Influenza Immunization in the U.S.: Strategies for Protecting Older Adults"
The National Foundation for Infectious Diseases (NFID) and mdBriefCase Grou=
p Inc. are offering a free, online CME training titled "Seasonal Influenza =
Immunization in the U.S.: Strategies for Protecting Older Adults."
http://messaging.aphanet.org/c/11trAaYjp1IRECPX6WPQgCzUwOV This training ca=
n be accessed on demand until February 18, 2018.
Upon completion of this activity, participants will be able to:
Describe the benefit of influenza vaccination in adults age 65 years and ol=
der
List the vaccine options available for seasonal influenza vaccination of ad=
ults age 65 years and older
Differentiate vaccine products approved for seasonal influenza in adults ag=
e 65 years and older
Effectively counsel older adult patients about the importance of seasonal i=
nfluenza vaccination
View the information page for more details about this activity.
http://messaging.aphanet.org/c/11trAiL23QTmC3Tvg6nUN1mcRK8 You can log on t=
o the training at the bottom of the information page.
Source: Immunization Action Coalition. IAC Express. Issue No. 1341. Decembe=
r 13, 2017.
CDC Has Rescheduled #PreteenVaxScene Webinar, =E2=80=9CAn Interprofessional=
Approach to HPV and Oropharyngeal Cancer Prevention Education,=E2=80=9D fo=
r February 21
http://messaging.aphanet.org/c/11trAyktnvemwW0Bypu3POUNxAy
CDC has rescheduled its #PreteenVaxScene webinar, =E2=80=9CAn Interprofessi=
onal Approach to HPV and Oropharyngeal Cancer Prevention Education,=E2=80=
=9D for February 21, 2:00 p.m. (ET). This webinar had originally been sched=
uled for January 8.
Register for the webinar.
http://messaging.aphanet.org/c/11trAG7c2koRun49Hz28mdH5SvL
Source: Immunization Action Coalition. IAC Express. Issue No. 1346. January=
24, 2018.
Register Now for the Annual California Immunization Coalition Summit, April=
16=E2=80=9317
http://messaging.aphanet.org/c/11trANTUH9zmrO7HQIAcSCtodqY
Register now for the 2018 California Immunization Coalition (CIC) Summit ti=
tled "Onward and Upward," which will be held in Sacramento on April 16=E2=
=80=9317. The CIC Summit web page
http://messaging.aphanet.org/c/11trAVGDlYJRpfbfZS8hp1fGymb provides informa=
tion and additional details, and it lists the following objectives for the =
event:
provide support and technical assistance to enhance existing education, com=
munication, and outreach efforts
facilitate the sharing of successful strategies and best practices to stren=
gthen local and statewide advocacy efforts
encourage the adoption of programs for healthcare providers to promote and =
deliver immunizations across the lifespan
review new recommendations, issues and trends in immunizations and vaccine-=
preventable diseases
View the draft agenda.
http://messaging.aphanet.org/c/11trB3tm0NUmmGeO91GlVq1YTho
Register for the CIC Summit.
http://messaging.aphanet.org/c/11trBbg4FD4Rk7imibeqrOOhecB
Related Link
California Immunization Coalition
http://messaging.aphanet.org/c/11trBj2NksfmhylUrkMuYdAzz7O website
Source: Immunization Action Coalition. IAC Express. Issue No. 1346. January=
24, 2018.
NFID 2018 Annual Conference on Vaccinology Research to Be Held April 23=E2=
=80=9325 in Bethesda
The National Foundation for Infectious Diseases (NFID) is holding the 2018 =
Annual Conference on Vaccinology Research (ACVR) on April 23=E2=80=9325 in =
Bethesda, Maryland.
Related Links
2018 Annual Conference on Vaccinology Research website
http://messaging.aphanet.org/c/11trBqPvZhpReZpsAukzuCmRU31
NFID's Online Education
http://messaging.aphanet.org/c/11trByCeE6Amcqt0JDSE119aeYe web page
Source: Immunization Action Coalition. IAC Express. Issue No. 1341. Decembe=
r 13, 2017.
Registration Now Open for CDC=E2=80=99s 48th National Immunization Conferen=
ce on May 15=E2=80=9317, 2018
Registration is now open for the 48th National Immunization Conference (NIC=
), scheduled for May 15=E2=80=9317
http://messaging.aphanet.org/c/11trBGoXiVKR9RwySNqIxpVszTr at the Hilton Ho=
tel in Atlanta.
http://messaging.aphanet.org/c/11trBVYoCA5R4JDFb6wRAdu3fJR brings together =
more than 1,500 local, state, federal, and private-sector immunization stak=
eholders and partners to explore science, policy, education, and planning i=
ssues related to immunization and vaccine-preventable diseases.
The NIC mission is to offer information that will help participants provide=
comprehensive immunization services for all age groups. The conference als=
o offers participants an opportunity to learn innovative strategies for dev=
eloping programs and policies, and for advancing science to promote immuniz=
ation among all ages today for a healthy tomorrow.
This three-day conference will include the following session tracks:
Adult Immunization
Immunization Information Systems
Programmatic Issues
Health and Risk Communications
Epidemiology and Surveillance
Childhood/Adolescent Immunization
Access the National Immunization Conference (NIC) web page
http://messaging.aphanet.org/c/11trC3L7hpgm2aHdkg4W6CglAF4, which includes =
information about conference and hotel registration, fees, abstract submiss=
ion, and more
Source: Immunization Action Coalition. IAC Express. Issue No. 1330. October=
11, 2017.
Registration is Open for the Epidemiology & Prevention of Vaccine-Preventab=
le Diseases ("The Pink Book") Course in Colorado, September 11=E2=80=93=C2=
=AD13
CDC faculty from its National Center for Immunization and Respiratory Disea=
ses will present a comprehensive review of immunization principles and reco=
mmendations for vaccines for vaccine-preventable diseases in a 2.5-day Epid=
emiology and Prevention of Vaccine Preventable Diseases (The Pink Book) cou=
rse.
http://messaging.aphanet.org/c/11trCbxPWeqQZBKLtpD0D12DVAh by the Colorado =
Children's Immunization Coalition and the Colorado Department of Public Hea=
lth and Environment Immunization Branch, the course will take place in Gree=
nwood Village, Colorado, on September 11=E2=80=9313.
View the course web page
http://messaging.aphanet.org/c/11trCjkyB3BlX2OjCzb59pOWgvu the Colorado Chi=
ldren's Immunization Coalition website.
View the course's draft agenda and details regarding CE credits available
http://messaging.aphanet.org/c/11trCr7hfSLQUtRRLIJ9FOBeBqH.
View registration information and register for the course.
http://messaging.aphanet.org/c/11trCyTZUHWlRUVpUShecdnwWlU
Source: Immunization Action Coalition. IAC Express. Issue No. 1344. January=
10, 2018.
Back to top
In This Issue
> News
> Resources
> Education
Follow Us:
Facebook
http://messaging.aphanet.org/c/11trCGGIzx6QPlYY41PiIC9Phh7
Twitter
http://messaging.aphanet.org/c/11trCOtremhlMN2wdbnnf0W7Cck
RSS
http://messaging.aphanet.org/c/11trCWg9TbrQKe64mkVrLpIpX7x
http://messaging.aphanet.org/c/11trD42Sy0ClHF9CvutwhOuIi2K
Acknowledgements: APhA appreciates the time and expertise of these individu=
als in creating the Immunizing Pharmacist News: Mitchel C. Rothholz, RPh, M=
BA, managing editor; LuGina Mendez-Harper, PharmD, medical writer.
----17C5E3F746EDDA92B065881187F6
Content-Type: text/html; charset="UTF-8"
Content-Transfer-Encoding: quoted-printable
w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
dth=3D"620">
|
|
|
|
![](3D"http://media.pharmacist.c=<BR) om/emailimages/Banners/Immunizing_Pharmacists-header.png" border=3D"0" alt=
=3D"Immunizing Pharmacist"> |
|
|
size: 12px; padding: 20px; color: #616f7d; text-align: left;" width=3D"360"=
valign=3D"top">
![](3D"http://echo.bluehornet.com/static/blueho=<BR) rnet/ems_templates/images/template2-div1.gif" alt=3D"" width=3D"345" height=
=3D"5">
color: #3f92d2;">News
: text; -webkit-user-drag: none; -webkit-tap-highlight-color: transparent; = font-family: 'Segoe UI', 'Segoe UI Web', Arial, Verdana, sans-serif; font-s= ize: 12px;"> g: 0px; user-select: text; -webkit-user-drag: none; -webkit-tap-highlight-c= olor: transparent; overflow: visible; cursor: text; clear: both; position: = relative; direction: ltr; z-index: 0;"> Widespread Influenza Has Killed 37 Children; CDC Provides Related Med=
ia Advisory
CDC has reported in its g.aphanet.org/c/11tqKjqPsaMDJobu8kRIryRL9Jk" target=3D"_blank">Weekly U.S. =
Influenza Surveillance Report, FluView, that as of the week ending Janu=
ary 20, influenza has caused nearly 12,000 hospitalizations and 37 ped=
iatric deaths since October 1, 2017. Because it takes time for deaths =
outside of a hospital to be investigated, the reported number of pedia=
tric deaths is likely to be an underestimate.
The geographic sprea=
d of influenza in Puerto Rico and 49 states was reported as widespread; Gua=
m reported regional activity; the District of Columbia and one state report=
ed local activity; and the U.S. Virgin Islands reported sporadic activity.<=
br>
On January 26, CDC held an update for the media titled "CDC U=
pdate on Flu Activity." Part of the introductory statement from Dan Je=
rnigan, MD, MPH, director, Influenza Division, National Center for Immuniza=
tion and Respiratory Diseases, CDC, is reprinted below.
It=
has been a tough flu season so far, this year. And while flu activity is b=
eginning to go down in parts of the country, it remains high for most the U=
.S., with some areas still rising. Most people with influenza are being inf=
ected with the H3N2 influenza virus. And in seasons where H3N2 is the main =
cause of influenza, we see more cases, more visits to the doctor, more hosp=
italizations, and more deaths, especially among older people. This season n=
ow looking like the 2014–15 season where H3N2 predominated. ... We&rs=
quo;ve experienced two notable characteristics of flu this season: The firs=
t is that flu activity became widespread within almost all states and juris=
dictions at the same time. The second is that flu activity has now stayed a=
t the same level for 3 weeks in a row, with 49 states reporting widespread =
activity, each week, for 3 weeks. We often see different parts of the count=
ry “light up” at different times, but for the past 3 weeks, the=
entire country has been experiencing lots of flu, all at the same time.&nb=
sp;
Access the 11tqKrdy6ZX8GPf2hupMXXE3uEx" target=3D"_blank">complete transcript or audio=
recording from this media advisory.
Influenza vaccinatio=
n is recommended for everyone six months of age and older. If you don't pro=
vide influenza vaccination in your clinic, please recommend vaccination to =
your patients and refer them to a clinic or pharmacy that provides vaccines=
or to the DXRumqlPzK" target=3D"_blank">HealthMap Vaccine Finder to locate s=
ites near their workplaces or homes that offer influenza vaccination servic=
es.
Following is a list of resources related to influenza disease =
and vaccination for healthcare professionals and the public:
Source: Immunization Action Coalition. IAC Express. Issue No=
. 1347. January 31, 2018.
CDC Publishes ACIP Recommendations for Use of Herpes Zoster Vaccines =
in MMWR
CDC published saging.aphanet.org/c/11tqLORtm4ODeCS5UbsAImdjcNQ" target=3D"_blank">Recomme=
ndations of the Advisory Committee on Immunization Practices for Use of Her=
pes Zoster Vaccines in the January 26 issue of MMWR&nb=
sp;(pages 103–8). The "Introduction" and "Clinical Guidance" sections=
are reprinted below:
Introduction
On Octo=
ber 20, 2017, Zoster Vaccine Recombinant, Adjuvanted (Shingrix, Glax=
oSmithKline), a 2-dose, subunit vaccine containing recombinant glyco=
protein E in combination with a novel adjuvant (AS01B), was approved by the=
Food and Drug Administration for the prevention of herpes zoster in adults=
aged ≥50 years. The vaccine consists of 2 doses (0.5 mL each), admin=
istered intramuscularly, 2–6 months apart. On October 25, 2017, t=
he Advisory Committee on Immunization Practices (ACIP) recommended the reco=
mbinant zoster vaccine (RZV) for use in immunocompetent adults aged ≥=
50 years.
Herpes zoster is a localized, usually painful=
, cutaneous eruption resulting from reactivation of latent varicella zoster=
virus (VZV). Herpes zoster is common: approximately one million cases occu=
r each year in the United States. The incidence increases with age, from fi=
ve cases per 1,000 population in adults aged 50–59 years to 11 cases =
per 1,000 population in persons aged ≥80 years. Postherpetic neuralgia, =
commonly defined as persistent pain for at least 90 days following the reso=
lution of the herpes zoster rash, is the most common complication and occur=
s in 10%–13% of herpes zoster cases in persons aged >50 years. Amo=
ng persons with herpes zoster, the risk for developing postherpetic neuralg=
ia also increases with age.
Zoster Vaccine Live (ZVL=
) (Zostavax, Merck and Co., Inc.), a 1-dose live attenuated s=
train of VZV, is licensed for the prevention of herpes zoster in immuno=
competent adults aged ≥50 years and is recommended by the ACIP for us=
e in immunocompetent adults aged ≥60 years. Since licensure, vaccine=
coverage has increased each year, and by 2016, 33% of adults aged ≥60 y=
ears reported receipt of the vaccine (CDC, provisional unpublished data). A=
CIP considered use of RZV, as well as existing recommendations, to develop =
vaccination policy which would be safe and reduce disease burden. This repo=
rt serves as a supplement to the 2008 Prevention of Herpes Zoster Recommend=
ations of ACIP for the use of ZVL in adults aged ≥60 years and subsequen=
t updates; it outlines recent ACIP recommendations as well as guidance for =
use of RZV and ZVL in adults.
Clinical Guidance
=
General use. RZV may be used in adults aged ≥50 years, irrespe=
ctive of prior receipt of varicella vaccine or ZVL, and does not require sc=
reening for a history of chickenpox (varicella). ZVL remains a recommended =
vaccine for prevention of herpes zoster in immunocompetent adults aged ≥=
60 years. Care should be taken not to confuse ZVL, which is stored in th=
e freezer and administered subcutaneously, with RZV, which is stored in the=
refrigerator and administered intramuscularly.
Dosing =
schedule. Following the first dose of RZV, the second dose shou=
ld be given 2–6 months later. The vaccine series need not be restarte=
d if more than 6 months have elapsed since the first dose; however, the eff=
icacy of alternative dosing regimens has not been evaluated, data regarding=
the safety of alternative regimens are limited, and individuals might rema=
in at risk for herpes zoster during a longer than recommended interval betw=
een doses 1 and 2. If the second dose of RZV is given less than 4 weeks aft=
er the first, the second dose should be repeated. Two doses of the vaccine =
are necessary regardless of prior history of herpes zoster or prior receipt=
of ZVL.
Timing of RZV for persons previously vaccinated wi=
th ZVL. Age and time since receipt of ZVL may be considered to deter=
mine when to vaccinate with RZV. Studies examined the safety and immunogeni=
city of RZV vaccination administered ≥5 years after ZVL; shorter interva=
ls have not been studied. However, there are no data or theoretical concern=
s to indicate that RZV would be less safe or less effective when administer=
ed at an interval of <5 years. Clinical trials indicated lower efficacy =
of ZVL in adults aged ≥70 years; therefore, a shorter interval may be co=
nsidered based on the recipient’s age when ZVL was administered. Base=
d on expert opinion, RZV should not be given <2 months after receipt of =
ZVL.
Coadministration with other vaccines. CDC&=
rsquo;s general best practice guidelines for immunization advise that recom=
binant and adjuvanted vaccines, such as RZV, can be administered concomitan=
tly, at different anatomic sites, with other adult vaccines. Concomitant ad=
ministration of RZV with Fluarix Quadrivalent (influenza vaccine) (QIV) has=
been studied, and there was no evidence for interference in the immune res=
ponse to either vaccine or safety concerns. Evaluation of coadministration =
of RZV with 23-valent pneumococcal polysaccharide vaccine (PPSV23, Pneumova=
x23) and tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis=
vaccine, adsorbed (Tdap, Boostrix) is ongoing. The safety and efficacy of =
administration of two adjuvanted vaccines (e.g., RZV and adjuvanted influen=
za vaccine [Fluad]), either concomitantly or at other intervals, have not b=
een evaluated.
Counseling for reactogenicity. B=
efore vaccination, providers should counsel RZV recipients about expected s=
ystemic and local reactogenicity. Reactions to the first dose did not stron=
gly predict reactions to the second dose; vaccine recipients should be enco=
uraged to complete the series even if they experienced a grade 1–3 re=
action to the first dose of RZV. The impact of prophylactic analgesics in c=
onjunction with RZV has not been studied.
Access the compl=
ete recommendation: 0TZ8c3VE3l0FeKZBxJ3" target=3D"_blank">Recommendations of the Advisory Comm=
ittee on Immunization Practices for Use of Herpes Zoster Vaccines.
=
Source: Immunization Action Coalition. IAC Express. Issue No. 1=
347. January 31, 2018. arget=3D"_self">Draft Agenda for February ACIP Meeting Available=
ACIP will hold its next meeting on February 21–22 in Atlanta. Th=
e draft agenda is now available online. To attend the meeting, ACIP at=
tendees (participants and visitors) must register online. The registration =
deadline for non-U.S. citizens is January 24; for U.S. citizens, it's Febru=
ary 5. Registration is not required to watch the meeting via webcast or lis=
ten to the proceedings via phone. See the first link below for the toll-fre=
e phone number and passcode.
Related Links |
|
 |
|
|
|
 |
|
|
|
